3 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 5 | Recruiting 3, Active not recruiting 1, Not yet recruiting 1 |
Follow Refractory Ewing Sarcoma: new trials by email Literature Review of Refractory Ewing Sarcoma trials Research Report on Refractory Ewing Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Lurbinectedin - Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Jazz Pharmaceuticals | 60 | 2023-05-23 | 2026-11-05 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Cabozantinib With Topotecan-Cyclophosphamide Cabozantinib, Topotecan, Cyclophosphamide - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 12 | 2020-12-23 | 2023-02-15 |
Sarcoma, Ewing (6) · Osteosarcoma (3) · Hepatoblastoma (2) · Neuroblastoma (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Wilms Tumor (2) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Desmoid Tumors (1) · Endometrial Neoplasms (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Neoplasms (1)
Neoplasms by Histologic Type (6) · Neoplasms, Bone Tissue (6) · Neoplasms, Connective Tissue (6) · Neoplasms, Connective and Soft Tissue (6) · Neoplasms (5) · Sarcoma (4) · Myosarcoma (3) · Neoplasms, Muscle Tissue (3) · Osteosarcoma (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2)
Specimen Handling (2) · Absorptiometry, Photon (1) · BAY 1895344 (1) · Bone Density (1) · Cyclophosphamide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · PM 01183 (1) · Phantoms, Imaging (1) · Temozolomide (1) · Topotecan (1) · X-Rays (1) · cabozantinib (1) · irinotecan sucrosofate (1) · pegfilgrastim (1)
Children's Oncology Group (2) · Dana-Farber Cancer Institute (1) · Jazz Pharmaceuticals (1) · National Cancer Institute (NCI) (1) · St. Jude Children's Research Hospital (1)
United States (5) · Canada (3)
Juan C Vasquez (1) · Michael V Ortiz (1) · Sara Federico, MD (1) · Sarah B Whittle (1) · Steven C DuBois, MD (1)
UM1CA228823 (3)